Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioBlock nasal spray against COVID-19
ISRCTN48554326Phase 2Completed
- Sponsor
- University of Tartu
- Start
- May 2021
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing BioBlock nasal spray with Placebo nasal spray (2 arms). Started May 2021; status: completed.
02
Drugs
anti-SARS-CoV-2 immunoglobulins (bovine colostrum)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN48554326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN48554326.